In ER-positive breast cancer cells, IGF-1R and ERα are often coexpressed and respond to the synergistic action of estrogen and IGF-1 signaling, leading to cross-talk between the ER and IGF-1R pathways [16,17]. Here, ESR1 is linked to breast carcinoma.